Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

NICE tuned down the GLP-1 agonist earlier this year ... overtaking Novo Nordisk’s older Victoza (liraglutide) product which requires dosing by injection every day. Ozempic is squaring off ...

The glucagon-like peptide-1 (GLP-1) analogue drug is already licensed to treat diabetes under the brand name Victoza ... Trial data showed that for a daily injection over 12 months, 34% lost ...

The GLP-1 liraglutide showed potential benefit in reducing stroke recurrence and improving functional outcomes after minor ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based ...

Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...

A human-derived, ultra-long-acting GLP-1 injection independently researched and developed by Innogen, a Shanghai-based medical technology enterprise, was recently approved for market by China's ...

Can GLP-1 Meds Harm Your Eyes? By Ernie Mundell HealthDay Reporter MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight loss ...

Now, diabetes specialists and cardiologists are among the specialists flocking to GLP-1 drugs to manage blood sugar and weight. In many ways, it's easier for physicians to access these drugs.